Option Care Health FY 2025 Earnings Snapshot

Option Care Health (OPCH) has wrapped up FY 2025 with fourth quarter revenue of US$1.5b and basic EPS of US$0.37, supported by trailing twelve month revenue of US$5.6b and EPS of US$1.28. Over recent periods, the company has seen revenue move from US$1.3b in Q4 2024 to US$1.5b in Q4 2025, while quarterly EPS shifted from US$0.36 to US$0.37 and trailing EPS moved from US$1.23 to US$1.28. With net profit margin at 3.7% compared with 4.2% a year earlier, the latest numbers put margins and earnings quality squarely in focus for investors.

See our full analysis for Option Care Health.

With the headline figures on the table, the next step is to see how these results line up with the widely followed stories around growth, profitability and risk that have formed around Option Care Health over the past year.

Net Margin Eases to 3.7%

• On a trailing basis, Option Care Health earned US$207.6m of net income on US$5.6b of revenue, which works out to a 3.7% net profit margin compared with 4.2% a year earlier.
• Consensus narrative points to investments in technology and clinical efficiency as long term margin supports. However, the recent move from a 4.2% to 3.7% margin shows that, in the near term, mix shifts into complex therapies and reimbursement pressures are still flowing through.
  • The long term story focuses on margin benefits from AI, analytics and higher acuity therapies. Over the last 12 months, though, net income was lower on a slightly higher revenue base versus the prior year (US$207.6m on US$5.6b compared with US$211.8m on US$5.0b).
  • This contrast means any bullish view on margin expansion needs to account for the fact that recent earnings growth was weaker than the 22.6% annualized gain seen over five years.

Revenue Builds, Profit Growth Stalls

• Quarterly revenue increased from US$1,346.4m in Q4 2024 to US$1,465.4m in Q4 2025, while net income in those quarters moved from US$60.1m to US$58.5m, showing higher sales alongside slightly lower profits.
• Analysts' consensus view highlights expansion in high growth infusion therapies and payer partnerships as drivers of sustained revenue growth. However, the fact that Q4 2025 net income is below Q4 2024 and trailing net income eased from US$213.8m to US$207.6m challenges the idea that top line gains are currently feeding through cleanly to the bottom line.
  • Consensus expects revenue to grow about 7.1% per year, yet over the most recent year earnings declined despite a five year earnings growth rate of 22.6% per year.
  • This combination of higher quarterly revenue and softer recent earnings suggests investors may need to examine how therapy mix, pricing and costs are interacting rather than assuming that volume growth alone supports the bullish case.

Have a look at how the community connects these revenue and earnings trends to long term growth expectations in our shared narratives for Option Care Health: See what the community is saying about Option Care Health

Mixed Signals on Valuation and Debt

• At a share price of US$33.82, Option Care Health trades below the DCF fair value estimate of US$60.89, while its trailing P/E of 25.9x sits slightly above the US healthcare industry average of 24.1x and well below the peer average of 64.7x.
• Consensus narrative highlights investments in technology, higher acuity care and capital deployment as factors supporting long term earnings expansion. At the same time, the combination of a high debt load, a net margin of 3.7% and recent negative earnings growth means the current premium to the industry P/E and discount to DCF fair value can be interpreted differently by bullish and cautious investors.
  • From a reward perspective, forecasts call for earnings growth of about 12% per year and the shares trade at a material discount to the US$60.89 DCF fair value, which supports a more optimistic stance.
  • From a risk perspective, margin compression from 4.2% to 3.7% and the flagged high level of debt provide data points for those who question how durable that earnings trajectory might be if reimbursement or mix trends shift further.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Option Care Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough to form a first impression, or are you still on the fence about the balance of risks and rewards here? If you want to move quickly from headline sentiment to hard numbers, it is worth checking the full picture of the company's profile through 2 key rewards and 1 important warning sign.

See What Else Is Out There

With net margin easing from 4.2% to 3.7%, softer recent earnings and a high debt load, Option Care Health's risk profile looks more exposed.

If that mix of thinner margins and heavier leverage makes you cautious, it could be worth checking companies in our 78 resilient stocks with low risk scores that prioritize resilience and balance sheet strength right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.